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Luminescent CaTiO3:Yb,Er Nanofibers Co-conjugated with Rose 
Bengal and Gold Nanorods for Potential Synergistic 
Photodynamic/Photothermal Therapy 
Yike Fua†, Heng Liua†, Zhaohui Rena, Xiang Lia*, Jie Huangb, Serena Bestc, Gaorong Hana* 
Photodynamic therapy (PDT) and photothermal therapy (PTT) have been explored widely for application in cancer 
treatment. In this work, we describe the synthesis of CaTiO3:Yb,Er (CTO) nanofibers co-conjugated with Rose Bengal (RB) 
and gold nanorods (AuNRs), which offer the potential for combined upconversion photoluminescence (UCPL) and 
enhanced, synergistic PDT and PTT. Based on this delivery platform, RB and AuNRs served as the PDT and PTT agents, 
respectively. RB and AuNRs have strong and well-matched absorption with the green and red emissions of UCPL CTO 
nanofibers respectively, hence a single 980 nm continuous wave laser with deep tissue penetration can be employed to 
allow PDT and PTT to occur simultaneously. The nanocomposite can effectively convert the near-infrared (NIR) radiation 
from the laser into a combination targeted hyperthermia and generation of reactive oxygen species (ROS). In comparison 
with PDT alone, the combined PDT/PTT treatment showed significantly enhanced suppression of the viability of Hep G2 
cells in vitro, demonstrating its potential for use in oncology. 
1 Introduction 
Mortality due to cancer is increasing year on year and in 2012, 
an estimated 14.1 million new cancer cases and 8.2 million 
cancer deaths occurred worldwide.1 Conventional cancer 
treatments including chemotherapy and radiotherapy are 
associated with a number of limitations, such as toxic side 
effects and the tendency towards multidrug resistance 
(MDR).2, 3 These treatments may also fail to eradicate the 
tumor as expected. In recent years, drug-free phototherapy 
including photothermal therapy (PTT) and photodynamic 
therapy (PDT) have attracted increasing attention due to their 
unique advantages, which include low toxicity, low level side 
effects, possibilities for remote control, potential for minimally 
invasive intervention and avoidance of chemo-resistance.4-9 
Near-infrared (NIR) illumination has been recognized to be 
ideal for phototherapy applications due to its deep tissue 
penetration. Previous reports describe a penetration depth of 
at least 10 cm through breast tissue, and 4 cm of skull/brain 
tissue or deep muscle using NIR laser sources.10 In general, PTT 
uses photo–absorbing agents to convert the electromagnetic 
energy of NIR light into localised heat and thereby destroy 
tumors via hyperthermia. For PDT, visible light converted by 
up-conversion nanomaterials under NIR light can activate 
photosensitizers (PSs) to generate cytotoxic reactive oxygen 
species (ROS), such as singlet oxygen (1O2), superoxide anions, 
and hydrogen peroxide, and thus reduce significantly the 
viability of tumor cells.11-13 However, issues such as low 
potency, the requirement for excessive laser power density, 
high oxygen dependence and long-term skin 
photosensitization have significantly hindered the clinical 
translation of both techniques.14 
Recent investigations have endeavored to develop 
synergistic therapeutic approaches in which PTT and PDT are 
combined effectively and simultaneously. Compared with 
individual treatment protocols, synergistic combined use of 
PTT and PDT can reduce the drawbacks of each method when 
used alone. Various types of nanocarriers, including gold 
nanomaterials8, 15, graphene16, and conjugated polymers17, 
have been tested for combined PDT and PTT. For example, 
PDT/PTT dual-mode therapeutic agents based on Chlorin e6 
(Ce6) modified poly(dopamine) nanospheres with high ROS 
generation and photothermal conversion efficiency was 
reported to offer significantly improved therapeutic effects as 
compared with PDT and PTT alone.11  
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To date, a variety of ultraviolet light or visible light 
responsive photosensitizers including Ce6 (660 nm) and 
Photofrin (630 nm) have been investigated.18-20 In such regions 
of the electromagnetic spectrum, light penetration is hindered 
due to endogenous chromophores and light scattering.21 
Therefore, two or more separate spectra with different 
wavelengths would normally be utilized for sequential 
excitation of each therapeutic step because of the absorption 
mismatch between photosensitizers and photothermal agents. 
However, sequential irradiation complicates and prolongs the 
treatment process owing to difficulties in focusing the two 
laser beams at the same position. Hence, constructing a novel 
therapeutic platform which can be triggered by a single 
wavelength laser for simultaneous PDT and PTT has become a 
hot topic in cancer therapy. 
Another problem associated with PDT and PTT 
monotherapies is the target specificity of particulate 
PS/photothermal agents or their carriers. The low efficiency of 
delivery of PS/photothermal agents to tumour sites limits 
effectiveness of the treatment. Implantable therapeutic 
platforms, such as hydrogels and polymeric films etc., have 
been considered as an ideal substitutes for delivering 
PS/photothermal agents, which can achieve a much higher 
concentration of agents at the cancerous site and low systemic 
agent levels simultaneously.22, 23 The design of 
phototherapeutic platforms based on the concept of localized 
drug delivery can maximize the effectiveness of PDT/PTT while 
minimizing the side effects of conventional therapy. 
Calcium titanate (CaTiO3) is a ceramic with excellent 
biocompatibility for medical implants.24-26 The construction of 
rare earth doped CaTiO3 nanofibers in our previous research 
also demonstrated the potential of capitalizing on the UCPL 
behaviour of CaTiO3 for drug delivery applications.27, 28 The 
rare earth ions doped, generally occupy the Ca site and the 
asymmetric perovskite structure of CaTiO3 can effectively 
prohibit the possible diffusion of rare earth elements, which 
ensures the photoluminescent properties and avoids potential 
toxicity. In an advancement our previous work, an implantable 
nanocomposite based on these CaTiO3 nanofibers has now 
been developed that allow us to combine PDT and PTT 
synergistically, in a way that offers the potential for a drug-free 
treatment regime. Rose Bengal (RB), a typical photodynamic 
therapeutic agent in the visible region, was attached to the 
surface of electrospun nanofibers comprising up-conversion 
photoluminescence (UCPL) CaTiO3:Yb,Er (CTO) (Figure 1). In 
addition, silica-coated gold nanorods (AuNR@SiO2) were 
prepared and anchored onto the nanofibers to serve as the 
photothermal agent. Using a single, 980 nm continuous wave 
laser, the red and green emissions from CTO nanofibers were 
absorbed by RB and AuNRs, generating a combination of heat 
and reactive oxygen species, respectively. The photothermal 
and photodynamic properties were analyzed systematically 
and an in vitro Hep G2 liver cancer cell model was utilized to 
evaluate the effects of the combined therapy compared with 
monotherapy. This work aims to find an effective approach for 
synergistic cancer therapy with superior efficacy. 
2 Results and discussion 
2.1 Characteristics of CTO nanofibers 
Electrospun CTO nanofibers were prepared using a sol-gel 
precursor and were calcined at 700 oC. It has been shown 
previously that this provided fibers with the optimum 
combination of surface roughness and crystallinity (without 
the formation of a second phase) in the case of subsequent 
attachment of active drug molecules.27 Representative 
 
Figure 1 Schematic diagram of synthesis process for CTO-RB-AuNR composite nanofibers. 
 
Figure 2 (a) SEM image and diameter distribution (inset) (b) TEM image and HRTEM pattern (inset) and (c) XRD pattern of 
calcined CTO:Yb,Er nanofibers. 
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scanning electron micrographs and transmission electron 
micrographs of the fibers produced in this study are shown in 
Figures 2a and 2b respectively. The inset image in Figure 2a 
shows that mean diameter of CTO nanofibers is approximately 
80 nm. Lattice imaging revealed a d-spacing of 0.273 nm, 
which is attributable to the (200) planes of CaTiO3 (JCPDS 
No.22-0153). Figure 2c shows well-defined X-ray diffraction 
peaks attributable to highly crystalline CaTiO3 (JCPDS No.22-
0153). The close match of the indexed reflections with the 
stick pattern suggests the absence of any extraneous Er or Yb 
compounds. 
2.2 Synthesis of CTO-RB nanocomposite 
To construct the CTO-RB composite, CTO nanofibers were first 
modified with amino groups to enhance the interaction between 
the two phases. FTIR spectra of CTO and amino-modified CTO 
nanofibers (CTO-NH2) are shown in Figure 3a. For pure CTO 
nanofibers, a characteristic peak at 548 cm-1 can be ascribed to a Ti-
O vibration. After modification using amino groups, a new peak 
appeared which can be assigned to N-H asymmetric bending 
vibration at 1560 cm-1, indicating the successful functionalization of 
CTO nanofibers with amino groups.  
To improve the reactivity of the carboxyl group for subsequent 
conjugation between RB and CTO nanofibers, the benzyl carboxyl 
group of RB was replaced with hexanoic acid (HA) to obtain RB-
HA.29 The FTIR spectrum of RB-HA in Figure 3a shows that a new 
peak corresponding to the C=O stretching vibration mode of the 
carboxyl group at 1720 cm-1, confirming the successful preparation 
of RB-HA. 
The nanofibers and photosensitizers were conjugated via 
electrostatic bonding between the amino group of CTO-NH2 
nanofibers and the carboxyl group of RB-HA. The C=O stretching 
vibration at 1720 cm-1 is absent in the FTIR spectrum of RBHA 
bound CTO nanofibers (CTO-RBHA, CTO-RB), whereas carboxylate 
bands at 1556 and 1390 cm-1 are detected, which indicates that 
proton transfer from the carboxylic acid of RB-HA to amino groups 
of the nanofibers has taken place.30 The findings confirm that RB-HA 
adsorbed on the nanofibers via electrostatic interaction. The zeta 
potential of pure CTO nanofibers is -16 mV. Amino modification 
induced positive zeta potential of approximately + 21.7 mV for CTO-
NH2 nanofibers, and the introduction of RB-HA neutralized part of 
the positive charge on CTO-NH2 nanofibers, resulting in a lower zeta 
potential of approximately + 6.5 mV (Figure 3b). The number of RB-
HA molecules attached to CTO nanofibers was determined to be 
1.77*1016 RB molecules per milligram of CTO nanofibers (Figure S1). 
Under 980 nm excitation, the CTO nanofibers emit green light 
(2H11/2, 4S3/2 →  4I15/2 transition) and red light (4F9/2 →  4I15/2 
transition) (Figure 4a, blue trace) confirming successful doping of 
rare earth ions into CaTiO3 crystal. The synergistic therapy platform 
is constructed based on the selective energy transfer from UCPL of 
CTO nanofibers to photosensitizers and AuNRs. RB was chosen in 
this study, because its absorption band at ~540 nm is overlapped by 
the green emission of CTO nanofibers when excited using radiation 
of 980 nm wavelength (Figure 4a). The absorption peaks of the 
CTO-RBHA complex around 500 – 600 nm present similar 
characteristics to the spectrum of pure RB-HA. The red shift 
observed may be attributed to the electron donating nature of the 
amine group.31 Therefore, the emission of ~540 nm was strongly 
 
 
Figure 3 (a) UV-vis absorption spectra of RB-HA and CTO-RBHA, and upconversion emission spectrum of CTO nanofibers 
under 980 nm irradiation; (b) Up-conversion emission spectra of CTO, CTO-RB and CTO-RB-Au under 980 nm irradiation. 
 
 
Figure 4 (a) FTIR spectra of RB molecules, RB-HA, CTO, CTO-NH2 nanofibers and CTO-RBHA nanocomposite;  (b) Zeta 
potentials of CTO, CTO-NH2, CTO-RBHA, AuNRs and AuNR@SiO2-COOH. 
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quenched while the emission of CTO nanofibers ~660 nm was 
almost unchanged after RB bonding, as demonstrated in Figure 4b, 
indicating the effective absorption of green emission by RB 
molecules. 
2.3 Characteristics of CTO-RB-Au composite 
AuNRs were prepared by a seed-mediated method with 
modifications.32 The as-prepared AuNRs were coated with a 
bilayer of CTAB, which acts as a stabilizer. The CTAB-coated 
AuNRs had an average length of ~ 33.3 ± 7 and a width of ~ 
14.4 ± 4 nm. The particles are crystalline with a d-spacing of 
0.233 nm, corresponding to the (111) lattice plane of gold 
(JCPDS No. 04-0784) (Figure 5a). While gold is biologically inert 
and surface-bonded CTAB has low cytotoxicity, detached CTAB 
is a harmful surfactant.33, 34 To reduce the potential hazards 
associated with this and also to improve photothermal 
stability, AuNRs were coated with silica.35, 36 The CTAB layer 
acts as an organic template for the silica coating via a modified 
Stöber method. As shown in Figure 5b, the AuNRs obtained 
were coated with a SiO2 layer with a thickness of 
approximately 10 nm. The corresponding UV-vis absorption 
spectra of AuNRs and AuNRs@SiO2 further confirm the 
successful silica coating of AuNRs (Figure 5c). The AuNRs have 
a weak transverse surface plasmon resonance (TSPR) band at 
520 nm and a strong longitudinal surface plasmon resonance 
(LSPR) band at 660 nm (as will be discussed below). After 
coating with SiO2, a clear red shift of ~20 nm in the LSPR band 
compared with that of uncoated AuNRs was observed, which is 
attributed to the increase in the local refractive index of the 
surrounding medium after replacing CTAB with SiO2 shell.37, 38  
In order to anchor the AuNRs on the CTO-RB nanofibers, the 
AuNR@SiO2 was modified with -COOH. The FTIR spectrum of 
AuNR@SiO2 reveals asymmetric stretching of Si-O-Si at 1087 
cm-1, symmetric stretching of Si-O-Si at 795 cm-1, a bending 
vibration for Si-O-Si at 467 cm-1 and symmetric stretching 
vibrations of Si-O bonds in the Si-OH groups at 960 cm-1, which 
can be attributed to the SiO2 layer (Figure 5d).38, 39 After being 
modified with -COOH groups, a clear vibrational peak at 1724 
cm-1 was observed, which can be assigned to the C=O 
stretching band of carboxylic groups. The zeta potential of 
AuNRs was found to be approximately + 27.1 mV. This was  
due to the bilayer of CTAB on the nanorod surface.40 After 
silica coating and -COOH modification, the charge on the 
AuNRs reversed to -17 mV, indicating the successful synthesis 
of AuNR@SiO2 –COOH (Figure 3b). 
The AuNR@SiO2-COOH obtained were conjugated to CTO-
RB via electrostatic bonding (CTO-RB-Au). After assembly of 
AuNRs, it was observed that AuNRs assembled at the surface 
of nanofibers (Figure 6a). The UV-vis absorption of CTO-RB-Au 
combined the absorption spectra of CTO-RB and AuNR@SiO2 
(Figure 6b). Under 980 nm excitation, the CTO nanofibers emit 
green light (2H11/2, 4S3/2 → 4I15/2 transition) and red light (4F9/2 
→  4I15/2 transition). As discussed previously, the green 
emission of CTO nanofibers under 980 nm irradiation was 
absorbed by RB molecules because of the overlap between RB 
molecules and green emission of CTO nanofibers. Comparing 
the UCPL spectrum of CTO nanofibers and the LSPR absorption 
of AuNRs, an overlap was also observed in the red part of the 
spectrum (Figure 6b). Therefore, the red emission was 
subsequently absorbed after the CTO-RB nanofibers were 
conjugated with AuNRs (Figure 4b). It should be noted that the 
aspect ratio of Au nanoparticles presents the plasmon 
wavelength of the longitudinal resonance. Careful tuning of 
the ratio between the length and diameter of the AuNRs 
results in an aspect ratio of ~ 2. In this study, a longitudinal 
 
 
Figure 6  (a) TEM and HRTEM (inset) images of AuNRs; (b) TEM 
image of AuNRs@SiO2, (c) UV-vis absorption spectra of AuNRs 







Figure 5 (a) TEM image of CTO-RB-Au nanocomposite; (b) UV-vis absorption spectra of CTO-RB, AuNR@SiO2 and CTO-RB-Au, 
and up-conversion emission spectrum of CTO nanofibers under 980 nm irradiation. 
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plasmon resonance band at ~660 nm was achieved, which is 
vital prerequisite for spectral matching to the red regime of PL 
emission from CTO nanofibers. This unique design enabled 
maximized absorption of emission from CTO nanofibers under 
980 nm irradiation and the consequent photothermal 
conversion. 
Therefore, the consistent absorption of RB molecules and 
AuNRs in the CTO-RB-Au nanocomposite implied that a single 
wavelength laser, that is 980 nm, can be used to excite both 
PDT and PTT simultaneously. 
2.4 Photothermal and photodynamic effects 
The temperature changes of aqueous solutions containing 
nanofibers of different concentrations under 980 nm laser 
irradiation (1.5 W/cm2) was investigated to examine the 
photothermal effect of CTO-RB-Au nanofibers. Figure 7a presents 
real-time photographs of the aqueous solutions with different 
amounts of nanofibers captured by an infrared thermal camera. The 
temperature of deionized water without nanofibers only increased 
by 6 °C after irradiation for 6 min (Figure 7b). In contrast, the 
temperature of CTO-RB-Au solution rose rapidly and strongly 
depended on the concentration of nanofibers. The temperature of 
the solution with a concentration of 200 μg/mL, dramatically 
increased from 27.1 °C to 53.4 °C within 6 minutes. The findings 
confirm that the CTO-RB-Au nanocomposites can rapidly and 
efficiently convert the energy from 980 nm laser into thermal 
energy. 
In addition to the photothermal effect, the ROS generation 
capability of CTO-RB-Au triggered by 980 nm light was also 
estimated using DPBF, a widely used chemical trapping 
reagent of 1O2 that can irreversibly react with 1O2.41, 42 Under 
the irradiation of 980 nm light, the absorption of DPBF at 410 
nm in pure DPBF solution remains unchanged (Figure 8). 
However, the absorbance of the solution containing CTO-RB-
Au and DPBF decreased gradually with the increasing of 
irradiation time, indicating the decomposition of DPBF. After 
12 min irradiation, ~ 50 % of DPBF was consumed, illustrating 
the efficient generation of singlet oxygen. 
2.5 In vitro study 
2.5.1 MTT assay 
To evaluate the potential for biomedical application, the 
biocompatibility of CTO, CTO-RB, and CTO-RB-Au was firstly 
investigated. Hep G2 cells were incubated with different 
concentrations of the materials for 24 h and were then evaluated 
using an MTT assay to quantify cell viability. The results show that 
the cell survival can be maintained above 89 % from the lowest 
concentration of 12.5 μg/mL to the highest of 200 μg/mL, 
confirming the satisfactory biocompatibility of the three samples 
(Figure 9a). In addition, the cell viability under the 980-nm 
irradiation (1.5 W/cm2) for 6 min was examined in the absence of 
the test materials (Figure 9a), to test the effect of the laser power 
alone. Survival of the Hep G2 cells remained at more than 90 %, 
implying that the toxicity presented by the laser power density was 
minimal. . 
As designed, the CTO-RB-Au nanocomposite has potential for 
both PDT and PTT when irradiated at 980 nm. To assess the 
synergistic effect in vitro, the Hep G2 cell viability was quantified by 
changing the concentration of the nanocomposites and exposure 
time, respectively. As shown in Figure 9b, most of the cancer cells 
stayed alive when incubated with pure CTO nanofibers even under 
irradiation of NIR light. The fact that there was some limited levels 
of cell death in the highest concentration of 200 μg/mL can be 
attributed to the slight temperature rise caused by NIR light. When 
 
 
Figure 8 ROS generated from CTO-RB-Au nanocomposite. (a) 
UV-vis absorption spectra of a mixture of DPBF with CTO-
RBHA-Au in ethanol under 980 nm irradiation (1.5W/cm2) for 
0-12 min respectively. (b) Consumption of DPBF over time in 






Figure 7 (a) Temperature images and (b) temperature variation 
of CTO-RB-Au nanocomposite solutions with different 
concentrations under irradiation by a 980-nm laser with a 
power density of 1.5W/cm2 for 6 minutes. 
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RB molecules were linked with CTO nanofibers there was a 
significant reduction in cell viability compared with pure CTO 
nanofibers and there was a dose-dependent photodynamic effect. 
A similar phenomenon was observed in the CTO-Au nanocomposite. 
About 60 % of Hep G2 cells were viable following single 
photodynamic or photothermal treatment with a concentration of 
25 μg/mL and exposure to irradiation for 6 min. While when CTO-
RB nanofibers were combined with AuNRs, the cell viability was 
dramatically decreased. Using a nanofiber concentration of 200 
μg/mL, the cell viability declined to only 15 %, while for the CTO-RB 
sample, the figure was ~43 %. This shows that the in vitro anti-
cancer efficacy of synergistic phototherapy is amplified 3 times as 
compared to the photodynamic approach alone. Moreover, as 
expected, the cell viability decreased with increasing irradiation 
time for the concentrations of 100 μg/mL and 25 μg/mL (Figure 
9c&d). The results demonstrate that the CTO-RB-Au nanocomposite 
combining PDT and PTT has the potential to deliver cancer therapy 
with significantly improved efficiency. 
 
Figure 10 The bright field and fluorescence images of Calcein AM and PI co-staining Hep G2 cells cultured with CTO, CTO-RB, CTO-Au 




Figure 9 Relative cell viability of Hep G2 cells incubated with CTO, CTO-RB, and CTO-RB-Au. Cell viability 
at different concentrations (12.5-200 μg/mL) for 24 h (a) in the absence and (b) presence of 980 nm 
irradiation (1.5 W/cm2) for 6 min. Cell viability depended on irradiation time (2-6 min) at concentration 
of (c) 25 μg/mL and (d) 100 μg/mL under 980 nm irradiation (1.5 W/cm2), *p < 0.05. 
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2.5.2 Live/dead cell staining 
The combined effects of PDT and PTT for CTO-RB-Au were further 
verified with Calcein AM and PI co-staining. Using 980 nm laser 
treatment, no obvious cell death was observed when cells were 
cultured with  the CTO nanofibers (Figure 10). However, in the CTO-
RB and CTO-Au group, the number of live cells decreased as 
compared with the control group, indicating the cytotoxicity of ROS 
and the heat effect generated by CTO-RB and CTO-Au under 
excitation by the 980-nm laser, respectively. Furthermore, cell 
death was dramatically increased with CTO-RB-Au, as indicated by 
the sparse green fluorescence from live cells. The results agree with 
the MTT assay in Figure 9, clearly demonstrating again the efficient 
PDT/PTT effect of the CTO-RB-Au composite. 
3 Conclusions 
In summary, CTO-RB-Au nanocomposites have been 
successfully fabricated for use in an implantable device 
designed for use with combined photodynamic and 
photothermal therapy. In the composite, RB and AuNRs served 
as the PDT and PTT agents, respectively. Since RB and AuNRs 
have matched absorption with the green and red emissions of 
UCPL CTO nanofibers respectively, a laser with continuous 
single wavelength can be employed to induce the PDT and PTT 
effects simultaneously. Using 980 nm irradiation, the 
nanocomposite can convert energy effectively from NIR light 
to induce a combination of heat and ROS generation.  
Moreover, the results from in vitro experiments demonstrated 
that this simultaneous therapeutic approach was significantly 
more effective than PDT alone. The synergistic combination of 
PDT and PTT thus holds promise for future applications in 
multiple anticancer therapies. 
4 Experimental section 
4.1 Synthesis of CTO nanofibers  
A method for the preparation and electospinning of CTO nanofibers 
has been reported previously.27, 28 Briefly, a typical sol-gel approach 
was used to prepare the precursor solution for electrospinning. 
Tetrabutyl titanate (~0.82 g), Ca(NO3)2·4H2O (∼0.45 g), 
Yb(NO3)3·5H2O (~0.19 g) and Er(NO3)3·5H2O (~0.02 g) were mixed 
with acetic acid (2 mL), ethanol (7 mL) and N, N-dimethylformamide 
(DMF, 3 mL) by stirring for 3 h. Then 0.6 g of poly(vinylpyrrolidone) 
(PVP，MW = 1,300,000, Aladdin), 0.2 g of Pluronic® F127 
(EO106PO70EO106) and 0.5 mL of acetyl acetone were added and 
stirred overnight to obtain a homogeneous solution. 
During the electrospinning process, the precursor was fed into a 
stainless-steel needle at 0.4 mL/h. When a voltage of 6-8 kV was 
applied to the needle, a stable cone-jet electrospinning mode was 
achieved and this was monitored using a high-speed camera 
(Baumer, TXG04h, Germany). Uniform precursor nanofibers were 
formed and collected on aluminum foil. After the product had been 
vacuum-dried at 80 °C for 12 h to remove the residual solvent, the 
nanofibers were calcined at 700 °C for 2 h in air.  
4.2 Surface decoration of CTO nanofibers  
CTO nanofibers were firstly modified with amino groups using a 
protocol adapted from work by Maldiney et al.43 and our previous 
work27, 28, in which 100 mg of CTO nanofibers were dispersed in 
NaOH aqueous solution (80 mL, 5 mM) under stirring for 12 h. Then 
the nanofibers were collected, washed, and dried. Thereafter, the 
obtained nanofibers were mixed with 500 μL of (3-aminopropyl) 
triethoxysilane (APTES, Aladdin) in 40 mL of DMF by stirring at 80 °C 
for 24 h. Then the amino modified CTO nanofibers were washed 
with DMF and collected by centrifugation. 
4.3 Linking of RB with CTO nanofibers 
To improve the reactivity of the carboxyl group for RB, RB hexanoic 
acid ester (RB-HA) was firstly synthesized using a method described 
by Lamberts et al..29 Briefly, 100 mg of RB was reacted with 20 mg 
of 6-bromohexanoic acid in 25 mL DMF at 70 °C for 24 h to obtain 
RB-HA aqueous solution. Subsequently, tris-(2-hydroxyethyl)-amine 
(TEA, 80 μL), N-hydroxysuccinimide (NHS, 60 mg) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, 
120 mg) were added into the RB-HA solution and stirred at 30 °C for 
1 h. Our novel step was to then introduce 60 mg of CTO-NH2 
nanofibers into the solution. The mixture was stirred for 24 h to 
obtain RB-HA conjugated CTO nanofibers. All experiments were 
undertaken in black-out conditions. 
4.4 Synthesis of gold nanorods  
4.4.1 Seed solution 
The gold nanorods (AuNRs) were fabricated according to the well-
established seed-mediated growth method with some 
modifications.32 Briefly, CTAB aqueous solution (5 mL, 0.2 M) was 
mixed with HAuCl4 (5 mL, 0.5 mM) and ice-cold NaBH4 (0.6 mL, 
0.01M) under vigorous stirring for 2 min. Then the brownish-yellow 
seed solution was aged at room temperature for 30 min before use.  
4.4.2 Growth solution 
The growth solution was made from solutions of CTAB (50 mL, 0.1 
M), sodium salicylate (0.16 g), HAuCl4 (50 mL, 1 mM), AgNO3 (1.2 
mL, 4 mM) and ascorbic acid (0.2 mL, 0.064 M). The growth solution 
became colorless after gentle stirring. The gold seed solution (0.16 
mL) was then injected into the growth solution and the mixture was 
stirred for 30 s and left undisturbed at 30 °C overnight. The gold 
nanorods obtained were centrifuged, washed with deionized water 
to removed excess CTAB and dispersed in 10 mL of water for 
further use. 
4.5 Synthesis of carboxyl-modified silica-coated gold nanorods 
Carboxyl-modified silica-coated gold nanorods (AuNR@SiO2-COOH) 
were prepared based on a modified version of a method reported 
previously.44, 45 The as-synthesized AuNRs in 10 mL of water was 
mixed with NaOH aqueous solution (0.1 mL, 0.1 M) under stirring. 
Then 100 μL of 5 % TEOS in methanol were added three times at 30 
min intervals, and the mixture was reacted for 12 h. The obtained 
AuNR@SiO2 were centrifuged, washed with deionized water several 
times, and re-dispersed in 5 mL of ethanol for further use.      
The AuNR@SiO2 solution and 40 μL of APTES were mixed in 40 
mL of DMF and stirred for 24 h. Then the obtained amino modified 
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AuNR@SiO2 (AuNR@SiO2-NH2) were centrifuged and redispersed in 
5 mL of ethanol.  
The AuNR@SiO2-NH2 solution, 40 mg of succinic anhydride (SA) 
and 40 mg of triethylamine were added into 5 mL DMSO and stirred 
in 40 °C for 48 h to obtain AuNR@SiO2-COOH. 20 mg of 
AuNR@SiO2-COOH and 40 mg of the CTO nanofibers were 
combined by stirring for 24 h to obtain a AuNR conjugated CTO 
nanocomposite (CTO-Au). Similarly, 20 mg of AuNR@SiO2-COOH 
and 40 mg of the CTO-RB composite were combined by stirring for 
24 h to obtain RB and AuNRs co-conjugated CTO nanocomposite. 
4.6 Examination of photothermal performance  
The photothermal effect of CTO-RB-Au solutions with different 
concentrations (0, 50, 100, 200 μg/mL) were estimated using a 980 
nm laser at a power density of 1.5 W/cm2 for up to 6 min at room 
temperature using a fiber coupled laser source (Stone laser system 
AC90-260V/50-60HZ, China). An infrared thermal imaging 
instrument (FLIR, E40) was used to measure and map the change of 
temperature.  
4.7 Detection of singlet oxygen generation 
Singlet oxygen generation irradiated by 980 nm light was measured 
by the absorption of a chemical probe, 3-diphenylisobenzofuran 
(DPBF). 2 mL of CTO-RB-Au ethanol solution (5 mg/mL) were mixed 
with 1 mL of DPBF ethanol solution (50 mM). Absorbance of the 
solution at 410 nm was recorded every 1 min. The generation of 1O2 
was determined from the decline of the absorption of DPBF. 
Absorption of DPBF solution under irradiation in the absence of 
materials was also recorded as a negative control. 
4.8 Preliminary in vitro study 
Human Hep G2 liver cancer cells were used to examine the in vitro 
antitumor potentials of CTO-RB-Au platform. The cytotoxicity of 
CTO, CTO-RB, CTO-Au and CTO-RB-Au was determined using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
cell assay. Hep G2 cells were seeded in a 96-well plate at a density 
of 8000 cells per well and incubated at 37 °C for 24 h. Then the 
culture media was replaced with fresh culture medium containing 
CTO, CTO-RB, CTO-Au and CTO-RB-Au nanocomposites at different 
concentrations. To study the photodynamic and photothermal 
effect, the nanocomposites were irradiated using a 980-nm laser for 
0-6 minutes with an energy density of 1.5W/cm2. After incubation 
for 24 h, 10 μL of MTT solution was added into each well and 
cultured for 4 h. Then the original medium was removed and 
formazan (MTT metabolic product) was dissolved with dimethyl 
sulfoxide (DMSO, 100 μL per well). The absorbance of the solution 
was measured at 490 nm using a microplate reader (Tecan 50, The 
Switzerland). The anticancer effect was further visualized using 
calcein acetoxymethyl ester (calcein AM) and propidium iodide (PI) 
staining and observed with a fluorescent microscope (Nexcope, The 
USA). The samples (not irradiated and/or not treated with 
nanocomposite) were used as a test control. Similarly, the 
cytocompatibility of samples was examined using an MTT assay 
with Hep G2 cells, following the same procedure above. 
 
4.9 Characterization 
The microstructure and morphology of materials were visualized by 
a Hitachi SU-70 field-emission scanning electron microscope 
(FESEM) and a FEI Tecnai F20 high-resolution transmission electron 
microscope (HRTEM). A thermo ARL X’TRA powder diffractometer 
was used to record the X-ray diffraction (XRD) patterns. FTIR 
spectra were evaluated using a Perkin-Elmer 580B infrared 
spectrophotometer (Tensor 27, Bruker). A Zetasizer (Zetasizer 3000 
HSA, Malvern) was used to determine the zeta potential of samples 
at room temperature. The UV-vis-NIR absorption spectra were 
examined by TU-1810 UV-vis spectrophotometer. The UCPL spectra 
were recorded using a fluorescence spectrophotometer (PL, 
FLSP920, Edinburgh) under the excitation of a 980 nm laser. The 
fiber diameter and the size of gold nanorods were measured from 
SEM or TEM micrographs using image analysis (n = 50). 
4.10 Statistical Analysis 
Data were expressed as mean ± standard deviation (SD). All 
statistical data were obtained using a two-tailed Student’s t test. A 
value of p < 0.05 was taken as statistically significant. 
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